Free Republic

It's every parent's nightmare, but true: Major U.S. corporations are funding a campaign of sophisticated, psychologically intrusive "gay" indoctrination programs targeting very young children in elementary schools across America. It’s part of a very well-planned and well-funded effort to reach children as young as possible without their parents’ intervention. The national program, called “Welcoming Schools”, skillfully works on the minds of young children in three ways: (1) Introducing the concept of homosexuality to children. (2) Telling them that homosexuality is normal and natural. (3) Telling them that their parents or friends who portray homosexuality in a less than positive way...

The Food and Drug Administration said yesterday that it would allow some patients in a clinical trial to resume treatment with Tysabri, a multiple sclerosis drug that was abruptly withdrawn from the market a year ago because of safety risks. The decision appears to strengthen the probability that Tysabri, developed by Biogen Idec and Elan, will be allowed to return to the market. The F.D.A. is scheduled to decide on that question by the end of March. "You can certainly deduce that we've concluded that there are at least some people for whom the risk is worth it," Dr. Robert...

The makers of the multiple sclerosis drug Tysabri said yesterday that a second patient who used the drug had been confirmed to be suffering from a rare but deadly brain infection. The confirmed diagnosis is likely to somewhat diminish the chances that the drug will be able to return to the market. The makers of the drug, Biogen Idec and Elan, halted sales and clinical trials on Monday, saying that one patient in a clinical trial had died from the brain infection and a second patient from the same trial, who was still alive, was also suspected of having it....

By THE ASSOCIATED PRESS BOSTON (AP) -- The makers of Tysabri, a new drug used to treat multiple sclerosis, announced Monday they are voluntarily suspending sales of the drug after one patient died and another developed a serious disease of the central nervous system.Stocks of both Biogen Idec Inc. and Elan Corp. tumbled, while shares of ther makers of rival MS drugs rose.The biotechnology companies said in a news release that they have suspended supplying and marketing the drug Tysabri and advised doctors to suspend prescribing the medication. The companies also have stopped using the drug in clinical trials.The companies...